United States (US) based pharmaceutical major Johnson & Johnson (J&J) is awaiting approval from the Drug Controller General of India (DCGI) to begin bridging trials for its single-dose COVID-19 vaccine, reports Economic Times.
J&J is also working with Hyderabad based vaccine maker Biological E to manufacture its vaccine in India as part of a global arrangement to supply the jabs across the world. The tie-up had been announced in August last year.
However, it should be noted that the government has already allowed the import of COVID-19 vaccines which have been approved by the USFDA, without any bridging trials.
Chairman of the National Expert Group on Vaccine Administration Committee (NEGVAC), Dr VK Pual had also reiterated on Thursday (13 May) that international vaccine makers like J&J are welcome to apply for an import licence and the government would issue an approval in two days.
Despite this, it is unclear why the company wants to conduct a bridging trial in India.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.